121 related articles for article (PubMed ID: 695793)
1. [Results of in vivo analysis of injected fibrinogen degradation products and factor VIII in patients with hemophilia A].
Kätzel R; Kubel M; Scheel H; Wegner H
Z Gesamte Inn Med; 1978 Aug; 33(15):525-9. PubMed ID: 695793
[TBL] [Abstract][Full Text] [Related]
2. [Occurrence and behavior of fibrin fibrinogen degradation products in concentrates of factor VIII, cryoprecipitate and dextran precipitate during long-term preservation].
Kätzel R; Wegner H
Z Gesamte Inn Med; 1977 Nov; 32(22):603-11. PubMed ID: 602311
[TBL] [Abstract][Full Text] [Related]
3. [Effect of plasma and/or factor VIII concentrates administration on platelet functions in patients with haemophilia A and von Willebrand's disease (author's transl)].
Gamba G; Grignani G; Nicolini E; Ascari E
Haematologica; 1975 Jun; 60(2):168-83. PubMed ID: 808449
[No Abstract] [Full Text] [Related]
4. Factor VIII concentrate for hemophilia: comparison of two heat-treated products.
Walker IR; Pai MK; Blair BA; Johnston MA; Birkett NJ; Ofosu FA; Naylor DH
CMAJ; 1987 Jan; 136(2):150-2. PubMed ID: 3098401
[TBL] [Abstract][Full Text] [Related]
5. In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.
Prowse CV
Thromb Haemost; 1995 Oct; 74(4):1191-6. PubMed ID: 8560434
[TBL] [Abstract][Full Text] [Related]
6. [Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].
Weippert M; Anders O; Schmidt M; Roewer J
Beitr Infusionsther; 1990; 26():174-8. PubMed ID: 1703823
[TBL] [Abstract][Full Text] [Related]
7. Immunologic dysfunction in patients with classic hemophilia receiving lyophilized factor VIII concentrates and cryoprecipitate.
Tsoukas C; Gervais F; Fuks A; Guttmann RD; Strawczynski H; Shuster J; Gold P
Can Med Assoc J; 1983 Oct; 129(7):713-7. PubMed ID: 6225504
[TBL] [Abstract][Full Text] [Related]
8. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
9. In vitro factor VIII recovery during the delivery of ultrapure factor VIII concentrate by continuous infusion.
DiMichele DM; Lasak ME; Miller CH
Am J Hematol; 1996 Feb; 51(2):99-103. PubMed ID: 8579073
[TBL] [Abstract][Full Text] [Related]
10. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
Gaerisch F; Stein P
Z Gesamte Inn Med; 1982 Oct; 37(19):641-4. PubMed ID: 6817530
[TBL] [Abstract][Full Text] [Related]
11. Danazol in Indian haemophiliacs.
Sundar S; Moorleedhur-Singh GS; Dube B; Singh VP; Kumar K
J Assoc Physicians India; 1993 Jan; 41(1):23-5. PubMed ID: 8340322
[TBL] [Abstract][Full Text] [Related]
12. Fibrinogen degradation products in fresh frozen plasma. Possible contribution to immunosuppression.
Donnell CA; Daniel SJ; Ferrara JJ
Am Surg; 1989 Aug; 55(8):505-7. PubMed ID: 2764399
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary experience with achieving immune tolerance in patients with hemophilia A and circulating factor VIII inhibitor].
Scharf R; Kucharski W; Lopaciuk S; Celińska W; Dmytrow A; Domański K; Gonet S; Miastkowski Z; Nowakowska I; Przybylski A
Acta Haematol Pol; 1991; 22(1):92-9. PubMed ID: 1823972
[TBL] [Abstract][Full Text] [Related]
14. Clearance of cryoprecipitated factor VIII in canine hemophilia A.
Aufderheide WM; Skinner SF; Kaneko JJ
Am J Vet Res; 1975 Apr; 36(4 Pt.1):367-70. PubMed ID: 1124873
[TBL] [Abstract][Full Text] [Related]
15. Lyophilised plasmas for one-stage determination of factor VIII.
Sikorová J; Vorlová Z
Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(6):906-13. PubMed ID: 6162757
[TBL] [Abstract][Full Text] [Related]
16. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
[TBL] [Abstract][Full Text] [Related]
17. [Paradoxical bleeding as a complication of the treatment of hemophilia with factor VIII and factor IX preparations].
Sutor AH
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):595-9. PubMed ID: 1714865
[TBL] [Abstract][Full Text] [Related]
18. [Substitutive treatment of hemopjolia A using a new factor VIII concentrate].
Allain JP; Steinbuch M; Meunier L; Muller JY; Soulier JP
Nouv Presse Med; 1976 Apr; 5(16):1047-50. PubMed ID: 1272773
[TBL] [Abstract][Full Text] [Related]
19. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
Briët E; Mauser-Bunschoten EP
Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158
[TBL] [Abstract][Full Text] [Related]
20. [Selected indicators of blood coagulation and fibrinolysis in articular exudates of patients with rheumatoid arthritis].
Dmoszyńska-Giannopoulou A; Kowalewski J; Pytko H; Szczepański L
Reumatologia; 1979; 17(2):157-60. PubMed ID: 472525
[No Abstract] [Full Text] [Related]
[Next] [New Search]
